EN DE
Watch Tonghua Golden-Horse Pharmaceutical Industry Co Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd stock ¥1.04, price ¥9.96, that is 89.6% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE000000735

TG Tonghua Golden-Horse Pharmaceutical Industry Co Ltd logo Thin data Nov 21, 2026

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd

000766 · SHE

Far too expensive (fair value 90% below the price) and falling price, but company just good enough: meets 1 of 3 rules.

Follow free in the weekly email
Generates free cash flow 
Quality 49/100 
Mixed Growth (revenue 5y −6.8 %/yr in CNY) 
Thin margins · 1.1% net margin (TTM) 
Moderate debt 
Revenue last quarter 26% below a year ago. 
Changed on Nov 21: ¥8.44 → ¥1.04 
Fair value ¥1.04 · Strongly overvalued 
Falling price (downtrend) 
Trails peers (0/14) 
Narrow moat 26/100
Thin data 
Extreme value
Watch Tonghua Golden-Horse Pharmaceutical Industry Co Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥29.50 ¥3.71 Fair Value ¥1.04 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

60‑month range ¥3.71 – ¥29.50 · fair‑value band ¥0.45 – ¥1.66 · the ¥9.96 price screens above the ¥1.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 21, 2026.

Follow Tonghua Golden-Horse Pharmaceutical Industry Co in your weekly email

Every Wednesday you see whether Tonghua Golden-Horse Pharmaceutical Industry Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China.

Show moreShow less

The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive medications, tonifying and restorative medicines, respiratory medication, diabetes medication, ENT medication, and pediatric medications.

It also offers Xiaojin pills, Tian Ranshexiang Xiaojin pills, Xiaokechuan capsules, Jiuwei Qianghuo granules, Xiongdan powder, Bear Bile powder, and Wenweishu tablets to treat glandular hyperplasia, inflammatory diseases, bone trauma and soft tissue injury, and other related diseases.

In addition, the company provides bacillus cereus live bacteria capsules, bacillus cereus live bacteria tablets are therapeutic live bacteria microecological preparations to treat enteritis, diarrhea, infantile diarrhea, and intestinal dysfunction.

The company was founded in 1990 and is headquartered in Tonghua, China.

Stock analysis

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) currently trades at ¥9.96, while our model-based Fair Value estimate is ¥1.04, 90% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of ¥1.58 per share, and 0 of the 22 models we run sit above the ¥9.96 price.

Bear case: the Earnings-Based group reads lowest at ¥0.58, and 22 of the 22 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥0.45 (bear) to ¥1.66 (bull), the price of ¥9.96 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd reported revenue of 1.2B CNY in FY2025 versus 1.5B CNY in FY2021, a compound −6.3%/yr. Reported net income was 34.3M CNY in FY2025, compounding −0.7%/yr from FY2021.

Key figures

Market cap 10.0B CNY (≈ $1.5B) Small · P/E ratio 498.0 · P/S ratio 9.84 · EPS (TTM) ¥0.02 · Dividend yield 0.6% · Net margin 1.1% · Return on equity 0.5% · Return on assets (EBIT) 1.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (medium confidence).

What moves the price

The share trades about 66% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at −90%, 000766 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (¥0.0500 to ¥6.42). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥0.45 Fair Value ¥1.04 Bull ¥1.66
Price ¥9.96 · Downside -89.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (¥0.0178 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥1.55 ¥1.58 ¥1.66 76
FCF DCF ¥0.0800 ¥1.10 ¥2.79 69
5Y Revenue Exit n/a ¥0.6800 ¥1.77 69
All 25 models by family
DCF Models
FCF DCF ¥0.0800 ¥1.10 ¥2.79 69
5Y Revenue Exit n/a ¥0.6800 ¥1.77 69
5Y EBITDA Exit ¥0.3300 ¥1.62 ¥3.21 69
5Y P/E Exit n/a n/a ¥0.3800 68
10Y Revenue Exit n/a ¥0.6800 ¥1.83 64
10Y EBITDA Exit ¥0.2300 ¥1.35 ¥2.99 61
10Y P/E Exit n/a ¥0.1300 >¥0.5200 61
Earnings-Based
Graham-Dodd ¥0.2400 ¥1.00 ¥1.37 64
Lynch FV ¥0.4100 ¥0.5800 ¥0.7500 61
PEG = 1.0 ¥0.4100 ¥0.5800 ¥0.7500 57
EPV n/a n/a ¥0.0200 68
Dividend Discount
Gordon GGM ¥0.7600 ¥1.55 ¥2.41 66
DDM Multi-Stage ¥0.7600 ¥1.32 ¥1.63 67
Multiples
P/E Multiple ¥0.5900 ¥0.7800 ¥0.9800 63
P/S Multiple ¥0.4500 ¥0.6000 ¥0.7500 58
P/B Multiple ¥4.81 ¥6.42 ¥8.02 55
EV/EBIT ¥0.0100 ¥0.5500 ¥1.08 56
EV/EBITDA ¥0.4100 ¥1.08 ¥1.74 62
EV/Revenue n/a ¥0.0500 >¥0.2000 50
Asset-Based
NCAV (Graham) ¥0.9900 ¥1.33 ¥1.98 54
Growth DCF
Growth DCF ¥0.0800 ¥1.04 ¥2.59 68
Rev-Margin DCF n/a ¥0.6700 ¥1.69 69
Economic Profit
Residual Income ¥1.55 ¥1.58 ¥1.66 76
ROIC Compounder n/a n/a ¥0.0200 68
Growth Earnings
Growth-Adj P/E ¥0.4500 ¥0.6400 ¥0.8300 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 44
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 59
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.8%
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
0.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.6%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.6% vs 13.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−32% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+61.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +58.4% a year for the price.

000766 screens overvalued: fair value 90% below the price. Compare with Merck KGaA →

Compare Tonghua Golden-Horse Pharmaceutical Industry Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 610 stocks

Beats the industry median on 0/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −89.6% · Bottom 25%
Profitability
Return on equity (12 months) 0.5% · Below median
Return on assets 0.8% · Below median
Net margin (12 months) 1.1% · Below median
Operating margin (12 months) 10.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) −25.9% · Bottom 25%
Dividend yield (12 months) 0.6% · Bottom 25%
Balance sheet
Debt / equity 0.69× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 498.0× · Priciest 25%
P/B 4.32× · Priciest 25%
P/S (12 months) 9.84× · Priciest 25%
Price / free cash flow (fiscal year) 243.5× · Priciest 25%
EV/EBITDA 76.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 23
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)2 · sector 26
HEALTH (low debt)66 · sector 96
DIVIDEND (yield)12 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.11 $113.53 +44% vs 000766
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.00 ¥52.43 +12% vs 000766
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,884.90 ₹1,982.92 +5% vs 000766
Haleon plc HLN $9.07 $8.47 −7% vs 000766
Merck KGaA MRK €146.45 €108.83 −26% vs 000766
Galderma Group GALD CHF 182.85 CHF 112.84 −38% vs 000766
Teva Pharmaceutical Industries Limited TEVA $39.23 $20.74 −47% vs 000766
Takeda Pharmaceutical Company TAK $21.77 $11.26 −48% vs 000766
Sandoz Group SDZ CHF 80.50 CHF 41.06 −49% vs 000766
Divi's Laboratories Limited DIVISLAB ₹11,180.50 ₹1,566.89 −86% vs 000766

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/000766

Frequently asked questions

Is Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) overvalued or undervalued?
As of Nov 21, 2026, our model estimates a fair value of ¥1.04 versus a price of ¥9.96, about 90% lower (overvalued).
What is the fair value of 000766?
Our model-based fair value for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is ¥1.04 (as of Nov 21, 2026), built from audited fundamentals. The current price: ¥9.96.
What is the quality score of 000766?
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
We do not set a price target; the yardstick is the fair value of ¥1.04 (as of Nov 21, 2026) from 25 valuation models. Cautious scenario ¥0.45, optimistic scenario ¥1.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Tonghua Golden-Horse Pharmaceutical Industry Co Ltd stock forecast for 2026?
Our models put fair value at ¥1.04, about 90% lower versus a price of ¥9.96 (overvalued). Cautious scenario ¥0.45, optimistic scenario ¥1.66. The calculation is refreshed regularly with new filings.
What is the revenue of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd reported trailing-twelve-month revenue of about 1.0B CNY (latest available figure, as of Nov 21, 2026).
Does Tonghua Golden-Horse Pharmaceutical Industry Co Ltd pay a dividend?
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd currently shows a dividend yield of 0.59% relative to its recent price (as of Nov 21, 2026).
How much is the dividend of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd has a dividend yield of 0.6%.
What growth is priced into Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
For today's price to be fair in a discounted-cash-flow model, Tonghua Golden-Horse Pharmaceutical Industry Co Ltd would have to grow free cash flow by 61.0 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 1.0 % per year. As of Nov 21, 2026.
What discount rate (WACC) does the fair value of 000766 use?
Our models discount Tonghua Golden-Horse Pharmaceutical Industry Co Ltd at 9.2 %: a base by market capitalisation (mid), damped by beta 0.53, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tonghua Golden-Horse Pharmaceutical Industry Co Ltd that is +61.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) delivered so far?
Over the past 5 years revenue at Tonghua Golden-Horse Pharmaceutical Industry Co Ltd grew 1.0 % a year. The price currently implies free-cash-flow growth of +61.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (+61.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The free-cash-flow yield on the price is 0.43 %: that much free cash flow Tonghua Golden-Horse Pharmaceutical Industry Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tonghua Golden-Horse Pharmaceutical Industry Co Ltd it is ¥1.04 per share (as of Nov 21, 2026), against a price of ¥9.96. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Tonghua Golden-Horse Pharmaceutical Industry Co Ltd stock overvalued or undervalued in 2026?
As of Nov 21, 2026, 000766 trades above its calculated fair value: price ¥9.96, fair value ¥1.04, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 000766?
No. The price is what the market pays today (¥9.96); the fair value is what the company's own numbers justify (¥1.04). For Tonghua Golden-Horse Pharmaceutical Industry Co Ltd the two are ¥8.92 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tonghua Golden-Horse Pharmaceutical Industry Co Ltd worth?
The market values Tonghua Golden-Horse Pharmaceutical Industry Co Ltd at about 10.0B CNY (market capitalisation, as of Nov 21, 2026). Per share that is ¥9.96; our models calculate a fair value of ¥1.04 per share.
What do the bullish and bearish scenarios say about 000766?
Our models span a range for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd: cautious scenario ¥0.45, base ¥1.04, optimistic ¥1.66 per share (as of Nov 21, 2026, price ¥9.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 000766?
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd trades at a price-to-earnings ratio of 498.0 (as of Nov 21, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥1.04 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings: 149.5. Other multiples: P/B 4.3, P/S 9.8, EV/EBITDA 76.8.
How solid is the balance sheet of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
Balance-sheet figures for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (as of Nov 21, 2026): return on equity 0.5%, debt of 0.69 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 000766 from its 52-week high?
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd trades at ¥9.96, about 66% below its 52-week high of ¥29.10 and at the low of ¥9.96 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.04 is for.
Which stocks are comparable to Tonghua Golden-Horse Pharmaceutical Industry Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tonghua Golden-Horse Pharmaceutical Industry Co Ltd stock attractive at the current price?
The data as of Nov 21, 2026: price ¥9.96, calculated fair value ¥1.04 (−90%), Quality Score 49/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 000766 calculated?
We run Tonghua Golden-Horse Pharmaceutical Industry Co Ltd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥1.04 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 9.6% above its aggregate fair value. Tonghua Golden-Horse Pharmaceutical Industry Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The closing price on Nov 20, 2026 was ¥9.96. Our model-based fair value is ¥1.04, about 90% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tonghua Golden-Horse Pharmaceutical Industry Co Ltd right now?
The price sits above even our optimistic bull case (¥1.66). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥0.45 to ¥1.66). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) come from?
Earnings per share at Tonghua Golden-Horse Pharmaceutical Industry Co Ltd grew 18.7 % a year from 2013 to 2024. Broken into its drivers: revenue per share +18.1 %, EBIT margin −0.9 %, tax rate −1.0 %, residual (interest, one-offs) +2.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd

How large is the market capitalisation of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The market capitalisation of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 10.0B CNY (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The price-to-sales ratio of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 9.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
Earnings per share at Tonghua Golden-Horse Pharmaceutical Industry Co Ltd are ¥0.02 (price ÷ EPS = P/E 498.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The dividend yield of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The net margin of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The return on equity (ROE) of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
On an EBIT basis the return on assets of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
The operating margin of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 10.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
Revenue at Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is down 25.9% versus a year earlier (3y avg −7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)?
Earnings per share at Tonghua Golden-Horse Pharmaceutical Industry Co Ltd are down 21.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) carry?
The net debt of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd is 1.5B CNY (fiscal year 2025, ≈ 37.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tonghua Golden-Horse Pharmaceutical Industry Co Ltd in the live analysis

One click puts Tonghua Golden-Horse Pharmaceutical Industry Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.